Semaglutide

A GLP‑1 receptor agonist with proven ASCVD benefit and strong weight loss is a great candidate drug for patients with cardiovascular disease and obesity. However, it is preferred for HFpEF and it has not been shown to reduce HFrEF hospitalization. It may be added later for weight or ASCVD risk, but it does not replace another cardioprotective drug for HF benefit as a first step.